45IN - Clinical trials with biological endpoints

Date 01 October 2012
Event ESMO Congress 2012
Session From biology to treatment in advanced pancreatic and gastroesophageal cancer
Topics Gastrointestinal Cancers
Translational Research
Presenter Arnaud D. Roth
Authors A.D. Roth
  • Oncology, University Hospitals of Geneva, CH-1211 - Geneva/CH

Abstract

Neoadjuvant chemotherapy or radiochemotherapy is a modality increasingly applied in the curative treatment of cancers of the esophagus and of the stomach. Complete pathological response (pCR) obtained after neoadjuvant therapy of esophageal cancer is an indicator of good prognosis (up to 70% at 5 years). However, a mean for earlier assessment of the efficacy of neoadjuvant therapy allowing to change regimen in case of no response or to go directly to surgery would be extremely welcome. Based on early reports of early extinction of PET-CT scan uptake in case of good response to chemotherapy in several tumor type, the MUNICON trial investigated this biological endpoint in esophageal cancer showing a fairly good correlation between PET-CT extinction and pathological response. Several trials aiming at the validation of these data have been started or are in preparation both in Europe and in the US. The strength and the weaknesses of this approach shall be discussed during this presentation.

Disclosure

All authors have declared no conflicts of interest.